Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia
Stock Information for Oncternal Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.